---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-018868"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2022-05-09T23:59:59+00:00"
generated_at: "2026-06-25T22:17:30.709025+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma Q1 2022 cash $98.7M; on track for registrational study in pulmonary sarcoidosis

## Summary
- Cash and investments $98.7M at March 31, 2022; R&D expenses $8.9M, G&A $3.5M.
- Phase 1b/2a efzofitimod data to be presented at ATS 2022; registrational study planned for Q3 2022.
- FDA orphan drug designation for efzofitimod in systemic sclerosis; exploring expansion into other ILDs.
- ATYR2810 IND candidate; Phase 1 study in cancer expected in H2 2022.

## SEC filing metadata
- accession: 0001564590-22-018868
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2022-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000156459022018868/0001564590-22-018868-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000156459022018868/life-8k_20220509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-018868
- JSON: https://secwatch.observer/filing/0001564590-22-018868.json
- Plain text: https://secwatch.observer/filing/0001564590-22-018868.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.